

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11)

EP 0 696 590 A1



(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
14.02.1996 Bulletin 1996/07

(51) Int. Cl.⁶: C07D 471/04, A61K 31/505
// (C07D471/04, 239:00, 221:00)

(21) Application number: 95109391.3

(22) Date of filing: 16.06.1995

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI

(30) Priority: 17.06.1994 JP 159322/94
17.06.1994 JP 159323/94
17.06.1994 JP 159324/94

(71) Applicant: NIPPON ZOKI PHARMACEUTICAL CO.,
LTD.
Chuo-ku, Osaka (JP)

(72) Inventors:


- Furukawa, Kazuhito,
c/o Ins. of Bio-Active Science
Yashiro-cho, Katoh-gun, Hyogo (JP)
- Hasegawa, Taisuke,
c/o Inst. of Bio-Active Science
Yashiro-cho, Katoh-gun, Hyogo (JP)

(74) Representative: Hansen, Bernd, Dr. Dipl.-Chem. et
al
D-81925 München (DE)

(54) Pyrido[2,3-d]pyrimidine derivatives, their preparation and their use as anti-asthma agents

(57) The present invention provides a rapid-acting remedy for asthma having a bronchodilating action.

A remedy for bronchial asthma containing the pyrido[2,3-d]pyrimidine derivatives represented by the general formula (A) or pharmaceutically acceptable salts thereof as an effective component.



wherein R¹ and R² are same or different and each of them is hydrogen, alkyl or benzyl; R³ is hydrogen, hydroxyl, dialkylaminomethyleneamino or -NH-X; X is hydrogen, alkyl, alkenyl, hydroxyl, amino, hydroxyalkyl, benzyl or acyl; R⁴ is hydrogen, alkyl, halogen, nitro, amino, hydroxyl, benzyloxy, cyano, carboxyl, alkoxy carbonyl, alkoxy sulfonyl, amino-sulfonyl, dialkylaminosulfonyl or sulfo; and R⁵ is hydrogen, alkyl or amino.

The rapid-acting remedy for bronchial asthma of the present invention which is capable of relieving the symptom of laboring breath at the onset of asthma due to its bronchodilating action can be used as a therapy not only for allergic asthma but also for various bronchial asthma such as endogenous asthma, exogenous asthma and dust asthma.

EP 0 696 590 A1

Description

The present invention relates to a remedy for bronchial asthma containing a pyrido[2,3-d]pyrimidine derivative or a pharmaceutically acceptable salt thereof as an effective component.

In modern society, there has been an increase in the number of patients suffering from bronchial asthma due to e.g. an increase in the use of automobiles. Bronchial asthma is a disease whose onset causes the spasticity of bronchial smooth muscles resulting in the patient being in a state of a very labored dyspnea. Bronchial asthma is classified as atopic, infectious or mixed depending upon the cause of its onset. It is believed that, usually, the so-called preparatory state of asthma is established by the addition of an acquired factor to the constitutional factor such as an increase in airway hypersensitivity to chemical mediators or other factors and then these interact with other factors causing predisposition such as antigen stimulation.


Antiallergic agents, expectorants, adrenocortical steroids and tranquilizers have been used as pharmaceutical agents for treating bronchial asthma as well as bronchodilators which directly act on the contracted bronchus to relax it. The antiallergic agent which is commonly used inhibits the liberation or the synthesis of chemical mediators such as histamine which participate in the establishment of an allergy or antagonize against it. Thus, such an antiallergic agent does not directly act as a therapeutic agent which dilates the contracted airway for relieving laboured breathing but instead prevents the onset of asthma symptoms associated with a chemical mediator. On the other hand, a bronchodilator is used as a rapid-acting therapeutical agent for relieving the symptom of laboured breathing caused by the onset of asthma.

The pyrido[2,3-d]pyrimidine derivatives described in the Japanese Laid-Open Patent Publication Sho-63/45279 exhibit an antiallergic action based upon an antagonistic action or liberation-inhibiting action against the chemical mediators such as histamine which is obvious from the description of the pharmacological test (PCA test) in the published gazette of said patent publication.

The present inventors have investigated substances which exhibit a bronchodilating action which is effective as a rapid-acting remedy upon the onset of asthma and found that certain pyrido[2,3-d]pyrimidine derivatives have an excellent bronchodilating action whereupon the present invention has been achieved.

Thus, an object of the present invention is to provide a rapid-acting remedy for bronchial asthma which is capable of relieving a symptom of laboured breathing as a result of its bronchodilating action at the onset of bronchial asthma.

The pyrido[2,3-d]pyrimidine derivatives which are contained as an effective component in the remedy for bronchial asthma of the present invention are compounds represented by the following general formula (A).



In the above general formula (A), R¹ and R² are the same or different and each of them is hydrogen, alkyl or benzyl; R³ is hydrogen, hydroxyl, dialkylaminomethyleneamino or -NH-X; X is hydrogen, alkyl, alkenyl, hydroxyl, amino, hydroxyalkyl, benzyl or acyl; R⁴ is hydrogen, alkyl, halogen, nitro, amino, hydroxyl, benzyloxy, cyano, carboxyl, alkoxy carbonyl, alkoxy sulfonyl, aminosulfonyl, dialkylaminosulfonyl or sulfo; and R⁵ is hydrogen, alkyl or amino.

In the above general formula (A), examples of the alkyl for R¹ or R² are linear or branched alkyls having one to six carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl and dimethylbutyl.

Examples of the alkyl in the dialkylaminomethyleneamino for R³ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of the alkyl for X in -NH-X for R³ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl; examples of the alkenyl therefor are linear or branched alkenyl having two to four carbon atoms such as ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl and sec-butenyl; examples of the hydroxyalkyl therefor are those wherein hydroxyl group(s) is/are substituted at the linear or branched alkyl having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl; and examples of


the acyl therefor are linear or branched acyl having one to four carbon atoms such as formyl, acetyl, propionyl, butyryl, isobutyryl and tert-butyryl as well as benzoyl.

Examples of the alkyl for R⁴ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl; examples of the halogen therefor are fluorine, chlorine, bromine and iodine; examples of the alkoxy carbonyl therefor are carbonyls to which a linear or branched alkoxy having one to four carbon atoms is bonded such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy; examples of the alkoxy sulfonyl therefor are sulfonyls to which the above-mentioned linear or branched alkoxy is bonded; and examples of the alkyl in the dialkylaminosulfonyl therefor are linear or branched alkyls having one to four carbons such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

Examples of the alkyl for R⁵ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.


Among the above-mentioned compounds represented by the general formula (A), the following compounds are novel substances and, since they exhibit both bronchodilating and antiallergic actions, they are very useful as the therapeutic and preventive agents for various allergic diseases, bronchial asthma, etc.

15 1) A compound represented by the general formula (1).




30 [in which, Ra¹ and Rb¹ are same or different and each of them is alkyl; Rc¹ is amino or alkylamino; and Re¹ is alkyl.]

2) A compound represented by the general formula (2).




45 [in which Ra² and Rb² are same or different and each of them is alkyl; and Rd² is alkoxy carbonyl.]

3) A compound represented by the general formula (3).




[in which Rc³ is amino, alkylamino or benzylamino.]

4) A compound represented by the general formula (4).




15 [in which one of Ra⁴ and Rb⁴ is hydrogen while another is alkyl; and Rc⁴ is amino or alkylamino.]

5) A compound represented by the general formula (5).



30 [in which Ra⁵ and Rb⁵ are different alkyl; and Rc⁵ is amino or alkylamino.]

6) A compound represented by the general formula (6).




45 [in which Ra⁶ is hydrogen or alkyl; and Rc⁶ is amino, alkylamino or benzylamino.]

50


55

7) A compound represented by the general formula (7).



15 [in which Ra⁷ and Rb⁷ are same or different and each of them is alkyl; and Rc⁷ is acylamino, alkylamino, benzylamino or dialkylaminomethyleneamino.]

8) A compound represented by the general formula (8).



30 [in which Ra⁸ and Rb⁸ are same or different and each of them is alkyl; Xc is hydrogen, alkyl or acyl; and Yd is alkyl, halogen, nitro, amino, hydroxyl, benzyloxy, cyano, carboxyl, alkoxy carbonyl, alkoxy sulfonyl, aminosulfonyl, dialkylaminosulfonyl or sulfo.]

35 In the above-mentioned general formula (1), examples of the alkyl for Ra¹ or Rb¹ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of the alkyl in the alkylamino for Rc¹ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of the alkyl for Re¹ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

40 In the above-mentioned general formula (2), examples of the alkyl for Ra² or Rb² are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of the alkoxy in the alkoxy carbonyl for Rd² are linear or branched alkoxy having one to four carbon atoms such as ethoxy, propoxy, isoproxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.

45 In the above-mentioned general formula (3), examples of the alkyl in the alkylamino for Rc³ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

In the above-mentioned general formula (4), examples of the alkyl for Ra⁴ or Rb⁴ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of the alkyl in the alkylamino for Rc⁴ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

50 In the above-mentioned general formula (5), examples of the alkyl for Ra⁵ or Rb⁵ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of the alkyl in the alkylamino for Rc⁵ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

55 In the above-mentioned general formula (6), examples of the alkyl for Ra⁶ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of the alkyl in the alkylamino for Rc⁶ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

In the above-mentioned general formula (7), examples of the alkyl for Ra⁷ or Rb⁷ are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of

the acyl in the acylamino for R_c⁷ are linear or branched acyls having one to four carbon atoms such as formyl, acetyl, propionyl, butyryl, isobutyryl and tert-butyryl as well as benzoyl; examples of the alkyl in the alkylamino therefor are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl; and examples of the alkyl in the dialkylaminomethyleneamino therefor are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

In the above-mentioned general formula (8), examples of the alkyl for R_a⁸ and R_b⁸ are linear or branched alkyls having one to six carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl and dimethylbutyl.

Examples of the alkyl for X_c are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl; and examples of the acyl therefor are linear or branched acyl having one to four carbon atoms such as formyl, acetyl, propionyl, butyryl, isobutyryl and tert-butyryl.

Examples of the alkyl for Y_d are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl; examples of the halogen therefor are fluorine, chlorine, bromine and iodine; examples of the alkoxy carbonyl therefor are carbonyls to which linear or branched alkoxy having one to four carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy is bonded; examples of the alkoxy sulfonyl therefor are sulfonyls to which the same linear or branched alkoxy having one to four carbon atoms as above are bonded; and examples of the alkyl in the dialkylaminosulfonyl therefor are linear or branched alkyls having one to four carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

Preferred compounds of the present invention are as follows:

- 20 1,3-Dimethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 1)
- 5-Amino-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 2)
- 5-Amino-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 3)
- 5-Amino-1-isobutyl-3-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 4)
- 25 1,3-Dimethyl-5-methylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 5)
- 1,3-Diethyl-5-methylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 6)
- 5-Allylamo-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 7)
- 1,3-Dimethyl-5-isopropylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 8)
- 30 1,3-Dimethyl-5-hydroxyaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 9)
- 1,3-Dimethyl-5-hydrazinopyrido[2,3-d]pyrimidine-2,4-dione (Compound 10)
- 1,3-Dimethyl-5-(2-hydroxyethyl)aminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 11)
- 1,3-Dimethyl-5-hydroxypyrido[2,3-d]pyrimidine-2,4-dione (Compound 12)
- 35 7-Amino-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 13)
- 6-Amino-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 14)
- 7-Amino-1,3-dimethyl-5-hydroxypyrido[2,3-d]pyrimidine-2,4-dione (Compound 15)
- 1,3-Dimethyl-5-tert-butylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 16)
- 40 7-Amino-1-isobutyl-3-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 17)
- 5-Amino-1,3-diethyl-6-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 18)
- 5-Amino-1,3-diethyl-6-fluoropyrido[2,3-d]pyrimidine-2,4-dione (Compound 19)
- 5-Amino-6-bromo-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 20)
- 45 5-Amino-1,3-diethyl-6-hydroxypyrido[2,3-d]pyrimidine-2,4-dione (Compound 21)
- 1,3-Diethyl-5-isopropylamino-6-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 22)
- 1,3-Diethyl-5-dimethylaminomethyleneamino-6-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 23)
- 5-Acetylamino-1,3-diethyl-6-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 24)
- 5-Benzylamino-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 25)
- 5-Diethyl-5-isopropylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 26)
- 5-Amino-1,3-diethyl-7-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 27)
- 5-Diethyl-5-isopropylamino-7-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 28)
- 5-Aminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 29)
- 50 5-Amino-3-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 30)
- 5-Amino-3-ethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 31)
- 5-Amino-1-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 32)
- 5-Amino-1-ethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 33)
- 5-Amino-3-ethyl-1-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 34)
- 55 5-Amino-1-ethyl-3-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 35)
- 5-Amino-1-benzylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 36)
- 5-Amino-1-benzyl-3-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 37)
- 5-Amino-1-benzyl-3-ethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 38)
- 5-Isopropylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 39)

5-Isopropylamino-3-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 40)
 3-Ethyl-5-isopropylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 41)
 5-Isopropylamino-1-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 42)
 1-Ethyl-5-isopropylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 43)
 5-Ethyl-5-isopropylamino-1-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 44)
 1-Ethyl-5-isopropylamino-3-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 45)
 1-Benzyl-5-isopropylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 46)
 1-Benzyl-5-isopropylamino-3-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 47)
 1-Benzyl-3-ethyl-5-isopropylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 48)
 5-Benzylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 49)
 1-Benzyl-5-benzylaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 50)
 5-Acetylamino-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 51)
 5-Benzoylamino-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 52)
 1,3-Dimethyl-5-dimethylaminomethyleneaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 53)
 5-Acetylamino-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 54)
 5-Benzoylamino-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 55)
 1,3-Diethyl-5-dimethylaminomethyleneaminopyrido[2,3-d]pyrimidine-2,4-dione (Compound 56)
 5-Amino-6-benzyloxy-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 57)
 5-Amino-6-cyano-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 58)
 5-Amino-1,3-diethyl-6-ethoxycarbonylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 59)
 5-Amino-6-carboxy-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 60)
 5-Amino-1,3-diethyl-6-methoxysulfonylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 61)
 5-Amino-6-aminosulfonyl-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 62)
 5-Amino-1,3-diethyl-6-diethylaminosulfonylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 63)
 5-Amino-1,3-diethyl-6-sulfopyrido[2,3-d]pyrimidine-2,4-dione (Compound 64)
 5-Amino-1,3-diethyl-6-nitropyrido[2,3-d]pyrimidine-2,4-dione (Compound 65)
 5,6-Diamino-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 66)
 7-Amino-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 67)
 7-Amino-1,3-diethyl-6-ethoxycarbonylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 68)
 1,3-Diethyl-5-formamidopyrido[2,3-d]pyrimidine-2,4-dione (Compound 69)
 1,3-Diethyl-5-formamido-6-methylpyrido[2,3-d]pyrimidine-2,4-dione (Compound 70)

The pyrido[2,3-d]pyrimidine derivatives according to the present invention include the pharmaceutically-acceptable salts of the compounds represented by the above-given general formula such as acid addition salts with hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid, perchloric acid, thiocyanic acid, boric acid, formic acid, acetic acid, haloacetic acid, propionic acid, glycolic acid, citric acid, tartaric acid, succinic acid, gluconic acid, lactic acid, malonic acid, fumaric acid, anthranilic acid, benzoic acid, cinnamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, sulfanilic acid, salts with alkali metal such as sodium or potassium, salts with alkaline-earth metal such as calcium or magnesium, or salts with other metals such as aluminum. The pyrido[2,3-d]pyrimidine derivatives of the invention may also include their metal complexes, for example, complexes with zinc, nickel, cobalt, copper, iron etc. Those salts and metal complexes may be manufactured from the pyrido[2,3-d]pyrimidine derivatives of the present invention in a free state or may be mutually converted from one to another by conventional means.

When the compounds of the present invention have stereoisomers such as cis-trans isomers, optical isomers, conformational isomers, etc. or exist in a form of hydrates, the present invention includes any of such stereoisomers and hydrates.

The compounds of the present invention may be manufactured by a method described in the Laid-Open Japanese Patent Publication Sho-63/45279 or by a method similar thereto. In addition, with respect to novel substances, the manufacturing method is described in more detail in the following examples.

50 (Examples)

Example 1.

(1) 1-Benzyl-5-chloropyrido[2,3-d]pyrimidine-2,4-dione (3 g) and 1 g sodium azide were dissolved in 30 ml of dimethyl formamide (DMF) and stirred at room temperature for 10 hours. The reaction solution was added to 400 ml of water, the separated crystals were filtered, dried, dissolved in 150 ml of methanol, 0.5 g of 10% palladium-carbon was added and the mixture was stirred in a hydrogen atmosphere at room temperature for 15 hours. The catalyst was removed, the filtrate was concentrated, the residue was dissolved in 1N hydrochloric acid, the solution was washed with chloroform and the aqueous layer was neutralized with 20% sodium hydroxide. The separated crystals

EP 0 696 590 A1

were extracted with chloroform, the organic layer was concentrated and the resulting crystals were recrystallized from ethyl acetate to give 1.5 g of the compound 36.

Melting point: 291.5-292°C

NMR(DMSO-d₆): 5.30(s,2H), 6.40(d,1H), 7.16-7.32(m,5H), 7.62(bs,1H), 7.90(d,1H), 8.19(bs,1H), 11.45(bs,1H)

5 1-Substituted, 3-substituted or 1,3-disubstituted-5-chloropyrido[2,3-d]pyrimidine-2,4-diones were similarly treated to give the following compounds.

(Compound 32)

Melting point: >300°C

NMR(DMSO-d₆): 3.38(s,3H), 6.39(d,1H), 7.58(bs,1H), 7.94(d,1H), 8.16(bs,1H), 11.33(bs,2H)

10 (Compound 33)

Melting point: >300°C

NMR(DMSO-d₆): 1.13(t,3H), 4.12(q,2H), 6.39(d,1H), 7.57(bs,1H), 7.95(d,1H), 8.17(bs,1H), 11.32(bs,1H)

15 (Compound 34)

Melting point: 211-212°C

NMR(DMSO-d₆): 1.14(t,3H), 3.46(s,3H), 3.91(q,2H), 6.42(d,1H), 7.62(bs,1H), 7.95(d,1H), 8.26(bs,1H)

20 (Compound 35)

Melting point: 246-247°C

NMR(DMSO-d₆): 1.16(t,3H), 3.24(s,3H), 4.20(q,2H), 6.42(d,1H), 7.60(bs,1H), 7.96(d,1H), 8.25(bs,1H)

25 (Compound 37)

Melting point: 187-188°C

NMR(DMSO-d₆): 3.26(s,3H), 5.37(s,2H), 6.44(d,1H), 7.16-7.33(m,5H), 7.66(bs,1H), 7.92(d,1H), 8.23(bs,1H)

30 (Compound 38)

Melting point: 187-188°C

NMR(DMSO-d₆): 1.15(t,3H), 3.93(q,2H), 5.37(s,2H), 6.45(d,1H), 7.16-7.3(m,5H), 7.68(bs,1H), 7.90(d,1H), 8.29(bs,1H)

35 (2) 5-Chloro-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione (5 g) and 3.5 g of isoprpylamine were dissolved in 70 ml of DMF and stirred at room temperature for 12 hours. The reaction solution was added to ice water and the separated crystals were filtered, dried and purified by a column of silica gel to give 4.9 g of the compound 26.

Melting point: 118-119°C

40 NMR(DMSO-d₆): 1.12(t,3H), 1.18(t,3H), 1.22(d,6H), 3.75-3.88(m,1H), 3.85(q,2H), 4.21(q,2H), 6.41(d,1H), 7.96(d,1H), 8.91(d,1H), 11.47(bs,1H)

45 1-Substituted, 3-substituted or 1,3-disubstituted-5-chloropyrido[2,3-d]pyrimidine-2,4-diones were similarly made to react with various substituted amines to give the following compounds.

(Compound 25)

50 Melting point: 111-112°C

NMR(DMSO-d₆): 1.15(t,3H), 1.17(t,3H), 3.93(q,2H), 4.21(q,2H), 4.56(d,2H), 6.45(d,1H), 7.2-7.4(m,5H), 8.05(d,1H), 9.57(t,1H)

(Compound 42)

Melting point: 215.8-216.6°C

55 NMR(DMSO-d₆): 1.22(d,6H), 3.39(s,3H), 3.81(dq,1H), 6.48(d,1H), 8.06(d,1H), 8.99(d,1H), 11.45(bs,1H)

(Compound 43)

Melting point: 227-228°C

NMR(DMSO-d₆): 1.14(t,3H), 1.21(d,6H), 3.82(dq,1H), 4.13(q,2H), 6.48(d,1H), 8.07(d,1H), 9.00(d,1H), 11.43(bs,1H)

(Compound 44)

Melting point: 141.0-141.5°C

NMR(DMSO-d₆): 1.14(t,3H), 1.23(d,6H), 3.47(s,3H), 3.84(dq,1H), 3.92(q,2H), 6.52(d,1H), 8.08(d,1H), 9.10(d,1H)

(Compound 45)

Melting point: 95-96.5°C

60 NMR(DMSO-d₆): 1.16(t,3H), 1.23(d,6H), 3.24(s,3H), 3.84(dq,1H), 4.21(q,2H), 6.51(d,1H), 8.08(d,1H), 9.10(d,1H)

(Compound 46)

Melting point: 205-206°C

NMR(DMSO-d₆): 1.22(d,6H), 3.82(m,1H), 5.31(s,2H), 6.49(d,1H), 7.16-7.33(m,5H), 8.02(d,1H), 9.01(d,1H), 11.56(bs,1H)

65 (Compound 47)

Melting point: 128-129°C

NMR(DMSO-d₆): 1.23(d,6H), 3.26(s,3H), 3.84(dq,1H), 5.39(s,2H), 6.52(d,1H), 7.15-7.33(m,5H), 8.04(d,1H), 9.12(d,1H)

70 (Compound 48)

Melting point: 136-137°C

NMR(DMSO-d₆): 1.15(t,3H), 1.23(d,6H), 3.84(dq,1H), 3.94(q,2H), 5.39(s,2H), 6.52(d,1H), 7.15-7.3(m,5H),
 5 8.03(d,1H), 9.13(d,1H)
 (Compound 50)
 Melting point: 223.4-224.6°C
 NMR(DMSO-d₆): 4.57(d,2H), 5.31(s,2H), 6.44(d,1H), 7.16-7.42(m,10H), 7.99(d,1H), 9.49(t,1H), 11.59(bs,1H)
 (Compound 51)
 Melting point: 196-197°C
 (Compound 52)
 Melting point: 243-244°C
 (Compound 53)
 Melting point: 149-150°C
 (Compound 54)
 Melting point: 141-142°C
 (Compound 55)
 Melting point: 191-192°C
 (Compound 56)
 Melting point: 100-101°C
 (Compound 69)
 Melting point: 163-164°C

20 Example 2.

The compound 46 (7.5 g) and 1 g of 10% palladium-carbon were added to 600 ml of acetic acid and stirred at 50°C for 15 hours. Active carbon was added to the reaction solution, heated to reflux for 30 hours, the insoluble matters were 25 filtered off and the filtrate was concentrated. Ethanol was added to the residue and the crystals were collected by filtration followed by drying to give 5 g of the compound 39.

Melting point: >300°C
 NMR(DMSO-d₆): 1.21(d,6H), 3.78(dq,1H), 6.39(d,1H), 7.94(d,1H), 8.79(d,1H), 11.18(bs,2H)

The compounds 36, 37, 38, 47, 48 and 50 were similarly treated to give the following compounds.
 30 (Compound 29)

Melting point: >300°C
 NMR(DMSO-d₆): 6.30(d,1H), 7.50(bs,1H), 7.84(d,1H), 8.01(bs,1H), 11.69(bs,2H)

(Compound 30)
 Melting point: >300°C
 35 NMR(DMSO-d₆): 3.17(s,3H), 6.34(d,1H), 7.55(bs,1H), 7.83(d,1H), 8.09(bs,1H)

(Compound 31)
 Melting point: >300°C
 NMR(DMSO-d₆): 1.11(t,3H), 3.85(q,2H), 6.33(d,1H), 7.55(bs,1H), 7.83(d,1H), 8.10(bs,1H), 11.38(bs,1H)
 (Compound 40)

40 Melting point: 240.5-241°C
 NMR(DMSO-d₆): 1.22(d,6H), 3.17(s,3H), 3.81(dq,1H), 6.41(d,1H), 7.96(d,1H), 8.90(d,1H), 11.48(bs,1H)

(Compound 41)
 Melting point: 249.5-250°C
 NMR(DMSO-d₆): 1.16(t,3H), 1.22(d,6H), 3.8(dq,1H), 3.85(q,2H), 6.41(d,1H), 7.96(d,1H), 8.9(d,1H)

45 (Compound 49)
 Melting point: >300°C
 NMR(DMSO-d₆): 4.54(d,2H), 6.34(d,1H), 7.22-7.42(m,5H), 7.92(d,1H), 9.27(t,1H), 11.21(bs,1H), 11.25(bs,1H)

Example 3.

50 (1) 5-Chloro-1,3-diethyl-6-methylpyrido[2,3-d]pyrimidine-2,4-dione was used instead of 1-benzyl-5-chloropyrido[2,3-d]pyrimidine-2,4-dione in the above-mentioned Example 1 (1) and the same reaction as in Example 1(1) was carried out to give the compound 18.

Melting point: 178-180°C
 55 NMR(DMSO-d₆): 1.14(t,3H), 1.15(t,3H), 2.03(s,3H), 3.93(q,2H), 4.19(q,2H), 7.0(bs,1H), 7.91(s,1H), 8.67(bs,1H)
 (2) 5-Chloro-1,3-diethyl-6-methylpyrido[2,3-d]pyrimidine-2,4-dione was used instead of 5-chloro-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione in the above-mentioned Example 1(2) and the same reaction as in Example 1(2) was carried out to give the compound 22.

Melting point: 119.5-120.0°C

EP 0 696 590 A1

NMR(DMSO-d₆): 1.14(t,3H), 1.16(t,3H), 1.20(d,6H), 2.29(s,3H), 3.93(q,2H), 4.19(q,2H), 4.2(dq,1H), 7.94(s,1H), 9.71(d,1H)

Example 4.

The compound 3 (2.3 g) was dissolved in 60 ml of tetrachloromethane, then 0.76 ml of pyridine and 1.6 g of bromine were added thereto and the mixture was heated to reflux for 1.5 hours. The reaction solution was concentrated and water was added to the residue followed by filtering to collect the crystals. They were washed with water and recrystallized from ethanol to give 30 g of the compound 20.

Melting point: 154-155°C

NMR(DMSO-d₆): 1.15(t,3H), 1.18(t,3H), 3.93(q,2H), 4.17(q,2H), 7.18(bs,1H), 8.31(s,1H), 8.94(bs,1H)

Example 5.

(1) The compound 18 (3 g) was dissolved in 10 ml of DMF, then 8.3 ml of dimethylformamide dimethylacetal were added thereto and the mixture was heated at 110°C with stirring overnight. The reaction solution was concentrated, hexane was added to the residue and the resulting crystals were filtered and recrystallized from hexane to give 2.8 g of the compound 23. The compound 23 was further treated with a column of silica gel and recrystallized from a mixed solvent of petroleum ether and benzene to give the compound 70.

(Compound 23)

Melting point: 174-175°C

NMR(DMSO-d₆): 1.10(t,3H), 1.18(t,3H), 2.05(s,3H), 3.01(s,6H), 3.89(q,2H), 4.25(q,2H), 7.40(s,1H), 8.19(s,1H)

(Compound 70)

Melting point: 142-143°C

(2) The compound 18 (2 g) was added to 20 ml of acetic anhydride and heated to reflux overnight. After it was well allowed to cool, the separated crystals were added to ether and the mixture was filtered followed by recrystallizing from ethanol to give 1.6 g of the compound 24.

Melting point: 157-158°C

NMR(DMSO-d₆): 1.12(t,3H), 1.25(t,3H), 2.14(s,3H), 2.20(s,3H), 3.91(q,2H), 4.30(q,2H), 8.79(s,1H)

Example 6.

(1) 1,3-Diethyl-7-methyl-5-(p-toluenesulfonyloxy)pyrido[2,3-d]pyrimidine-2,4-dione was used instead of 1-benzyl-5-chloropyrido[2,3-d]pyrimidine-2,4-dione in the above-mentioned Example 1 (1) and the same reaction as in Example 1(1) was carried out to give the compound 27.

Melting point: 198.5-199.0°C

NMR(DMSO-d₆): 1.13(t,3H), 1.16(t,3H), 2.27(s,3H), 3.91(q,2H), 4.19(q,2H), 6.28(s,1H), 7.48(bs,1H), 8.16(bs,1H)

(2) 1,3-Diethyl-7-methyl-5-(p-toluenesulfonyloxy)pyrido[2,3-d]pyrimidine-2,4-dione was used instead of 5-chloro-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione in the above-mentioned Example 1 (2) and the same reaction as in Example 1 (2) was carried out to give the compound 28.

(Compound 28)

Melting point: 92-93°C

NMR(DMSO-d₆): 1.13(t,3H), 1.16(t,3H), 1.22(d,6H), 2.34(s,3H), 3.82(dq,1H), 3.91(q,2H), 4.20(q,2H), 6.40(s,1H), 8.99(d,1H)

Example 7.

5-Chloro-1,3-diethyl-6-fluoropyrido[2,3-d]pyrimidine-2,4-dione (6.2 g) and 50 ml of 28% ammonium hydroxide were heated at 150°C for 2 hours in a simple polymerizing device. After cooling, the mixture was extracted with chloroform, the extract was dried with sodium sulfate and the solvent was evaporated therefrom. The resulting crystals were recrystallized from ethanol to give 4.5 g of the compound 19.

Melting point: 201-202°C

NMR(DMSO-d₆): 1.15(t,3H), 1.16(t,3H), 3.92(q,2H), 4.18(q,2H), 7.69(bs,1H), 8.17(d,1h), 8.31(bs,1H)

5-Chloro-1,3-diethyl-6-benzyloxypyrido[2,3-d]pyrimidine-2,4-dione was treated by the same manner as above to give the compound 57.

Melting point: 213-215°C

NMR(DMSO-d₆): 1.14(t,3H), 1.15(t,3H), 3.92(q,2H), 4.16(q,2H), 5.19(s,1H), 6.9-7.0(bs,1H), 7.3-7.6(m,5H), 7.94(s,1H), 8.3-8.4(bs,1H)

Example 8.

The compound 57 (5 g) was suspended in 300 ml of methanol and subjected to a catalytic reduction at room temperature in the presence of 500 mg of 10% palladium-carbon. When the crystals of the benzyloxy compound (the compound 57) disappeared after about 1 hour, the catalyst was filtered off and the solvent was evaporated from the filtrate. The residual crystals were recrystallized from ethanol to give 1.4 g of the compound 21.

Melting point: 213-215°C

NMR(DMSO-d₆): 1.14(t,3H), 1.15(t,3H), 3.92(q,2H), 4.16(q,2H), 6.5-7.0(bs,1H), 7.71(bs,1H), 7.9-8.3(bs,1H), 9.63(s,1H)

Example 9.

DMF (30 ml) was added to 4.2 g of potassium cyanide, 0.7 g of palladium diacetate and 3.3 g of triphenylphosphine, the mixture was stirred at room temperature for 30 minutes in an argon atmosphere and a solution of 10 g of the bromo compound (the compound 20) in 20 ml of DMF was added thereto. The reaction solution was stirred at 90°C for 24 hours, poured into ice water and extracted with ethyl acetate. The organic layer was washed with a saturated sodium chloride solution and dried with sodium sulfate. The solvent was evaporated and the residue was purified by a column of silica gel followed by recrystallizing from benzene to give 3.5 g of the compound 58.

Melting point: 193-195°C

NMR(DMSO-d₆): 1.15(t,3H), 1.17(t,3H), 3.92(q,2H), 4.20(q,2H), 8.04(bs,1H), 8.54(s,1H), 9.06(bs,1H)

20

Example 10.

(1) Raney nickel was added to an ethanolic solution of 1 g of 5-amino-1,3-diethyl-6-ethoxycarbonyl-7-methylthiopyrido[2,3-d]pyrimidine-2,4-dione and the mixture was heated to reflux for 5 hours. The catalyst was removed using celite, the filtrate was concentrated, the residue was purified by a column of silica gel and the resulting crystals were recrystallized from ethanol to give 6.0 g of the compound 59.

Melting point: 144-145°C

NMR(DMSO-d₆): 1.16(t,3H), 1.18(t,3H), 1.32(t,3H), 3.93(q,2H), 4.23(q,2H), 4.30(q,2H), 8.49(d,1H), 7.86(s,1H), 9.36(d,1H)

30

(2) The compound 59 (0.56 g) was added to 10 ml of ethanol, 1 g of potassium hydroxide and 10 ml of water and the mixture was heated to reflux for 10 minutes. The reaction solution was acidified with acetic acid and the separated crystals were filtered followed by washing with water to give 0.46 g of the compound 60.

Melting point: 264-266°C

NMR(DMSO-d₆): 1.16(t,3H), 1.18(t,3H), 1.32(t,3H), 3.93(q,2H), 4.23(q,2H), 8.70(d,1H), 8.72(s,1H), 9.28(d,1H)

35

Example 11.

(1) The compound 3 (1 g) was added to 3 ml of chlorosulfuric acid and stirred at 100°C for 2 hours. The reaction solution was added to ice water and the separated crystals were filtered followed by washing with water to give 1.1 g of 5-amino-6-chlorosulfonyl-1,3-diethylpyrido[2,3-d]pyrimidine-2,4-dione.

(2) The above product (3 g) was dissolved in 30 ml of tetrahydrofuran and 20 ml of methanol, then a sodium methoxide solution prepared from 300 mg of sodium and 10 ml of methanol was added thereto and the mixture was stirred for 30 minutes. Acetic acid was added to the reaction solution to make it acidic and the solvent was evaporated therefrom. Water was added to the residue, the mixture was extracted with chloroform, the organic layer was dried with sodium sulfate, the solvent was evaporated therefrom and the residue was purified by a column of silica gel followed by recrystallizing from methanol to give 2.1 g of the compound 61.

Melting point: 156-157°C

NMR(DMSO-d₆): 1.16(t,3H), 1.20(t,3H), 3.77(s,3H), 3.93(q,2H), 4.24(q,2H), 7.28(bs,1H), 8.55(s,1H), 9.51(bs,1H)

50

(3) The product in the above-mentioned (1) was similarly treated with ammonia, diethyl ammonium and sodium hydroxide to give the compounds 62, 63 and 64, respectively.

(Compound 62)

Melting point: 236-238°C

NMR(DMSO-d₆): 1.16(t,3H), 1.18(t,3H), 3.94(q,2H), 4.22(q,2H), 7.19(bs,1H), 7.61(bs,2H), 8.50(s,1H), 9.41(bs,1H)

(Compound 63)

55

Melting point: 168-169°C

NMR(DMSO-d₆): 1.07(bz2,3Hx2), 1.15(t,3H), 1.19(t,3H), 3.25(qx2,2Hx2), 3.92(q,2H), 4.23(q,2H), 7.34(bs,1H), 8.49(s,1H), 9.39(bs,1H)

(Compound 64)

Melting point: >320°C

NMR(DMSO-d₆): 1.13(t,3H), 1.15(t,3H), 3.92(q,2H), 4.19(q,2H), 7.46(d,1H), 8.30(s,1H), 8.87(d,1H)

Example 12.

(1) A mixture of 40 ml of nitric acid and 40 ml of concentrated sulfuric acid was cooled with an ice bath and 10 g of the compound 3 were added. Temperature of the reaction solution was made room temperature, the solution was stirred for 1 hour, then stirred at 50°C for 1 hour, added to ice water and the mixture was extracted with chloroform. The organic layer was dried with sodium sulfate, the solvent was evaporated therefrom and the resulting crystals were recrystallized from methanol to give 9.1 g of 1,3-diethyl-5-nitroaminopyrido[2,3-d]pyrimidine-2,4-dione.
 (2) The above product (5.3 g) was dissolved in 20 ml of sulfuric acid and stirred at 50°C for 30 minutes. The reaction solution was added to ice water, neutralized with 28% aqueous ammonia and extracted with chloroform. The organic layer was dried with sodium sulfate, the solvent was evaporated therefrom and the resulting crude crystals were recrystallized from methanol to give 3.3 g of the product 65.

Melting point: 169-170°C

NMR(DMSO-d₆): 1.17(t,3H), 1.20(t,3H), 3.94(q,2H), 4.26(q,2H), 8.81(bs,2H), 9.15(s,1H), 9.94(bs,1H)

(3) The compound 65 (2.9 g) was dissolved in 60 ml of ethyl acetate, 0.5 g of 10% palladium-carbon was added and the mixture was stirred at room temperature for 1 hour in a hydrogen atmosphere. The catalyst was filtered off using celite, the resulting filtrate was concentrated and the separated crystals were recrystallized from methanol to give 1.6 g of the compound 66.

Melting point: 198-199°C

NMR(DMSO-d₆): 1.14(bx2,3Hx2), 3.92(q,2H), 4.15(q,2H), 4.62(bs, 1H), 7.64(s,1H), 6.5-8.5(bs,2H)

Example 13.

6-Amino-5-formyl-1,3-diethyluracil was treated by the same manner as mentioned in Example 5 of the Laid-Open Japanese Patent Publication Sho-63/45279 to give the compound 67.

Melting point: 203-204°C

NMR(DMSO-d₆): 1.13(t,3H), 1.19(t,3H), 3.91(q,2H), 4.18(q,2H), 6.32(b,1H), 7.20(bs,2H), 7.88(d,1H)

Example 14.

6-Amino-1,3-diethyluracil (3.0 g) and 3.4 g of ethyl 2-ethoxymethylene-2-cyanoacetate were stirred at 170°C for 1 hour in an argon atmosphere. After cooling, methanol was added thereto, the resulting crystals were filtered and dried and the resulting mixture was purified by means of a flash column followed by recrystallizing from ethanol to give the compound 68.

Melting point: 203-204.5°C

NMR(DMSO-d₆): 1.13(t,3H), 1.20(t,3H), 1.34(t,3H), 3.89(q,2H), 4.16(q,2H), 4.29(q,2H), 7.98(bs,1H), 8.12(bs,1H), 8.52(s,1H)

Now the bronchodilating action of the pyrido[2,3-d]pyrimidine derivatives of the present invention will be described in detail as hereunder.

A guinea pig was sacrificed by draining out its blood, its trachea was extracted and incised along the tracheal cartilage and four tracheal slices with a width of about 1 mm were connected with a silk yarn to give a sample of tracheal smooth muscle. The sample was suspended, with a load by a tension of about 0.5 g, in a 5 ml Magnus vessel (31°C) which was filled with a Tyrode solution and aerated with a mixture of 95% oxygen and 5% carbon dioxide. When the base line became stable after allowing the sample to stand for 0.5-1 hour, histamine dihydrochloride was made to act therewith and the resulting isotonic contraction was recorded through an isotonic transducer.

Investigation of the bronchodilating action of the test compounds was conducted using a relaxing action to the sustained contracting reaction by the contracting agent as an index. Thus, after the sustained contracting reaction of the smooth muscle by 10⁻⁴M histamine dihydrochloride became constant, the test compound was made to act therewith at a concentration of 10⁻⁵M, the relaxation rate to the sustained contracting height was calculated and the activity was evaluated in terms of the strength of said relaxation rate. The length of tracheal smooth muscle relaxed by the test compound divided by the sustained length contracted by histamine dihydrochloride is called the relaxation rate.

An example of the results of the experiments is given in the following Table 1.

TABLE 1

Compound No.	Relaxation Rate (%)	Compound No.	Relaxation Rate (%)	Compound No.	Relaxation Rate (%)
2	33.3	32	25.7	53	25.0
3	130.8	33	47.9	54	82.8
4	85.7	34	72.9	55	38.3
10	6	35	107.9	56	93.3
17	100.0	36	18.2	57	93.8
18	110.8	37	48.1	58	115.9
15	19	38	93.0	59	35.4
20	103.4	39	100.0	60	18.3
21	99.0	40	60.0	61	62.1
22	134.4	41	65.8	62	43.4
24	20.6	42	73.3	63	67.9
25	100.0	43	72.9	65	100.0
26	29.2	44	104.2	66	90.3
27	84.3	45	53.2	67	98.4
28	148.0	46	46.5	68	27.1
29	12.5	47	29.8	69	96.2
30	12.2	48	13.8	70	117.6
31	21.2	51	18.2		

(2) Antiallergic Action.

The antiallergic action of the compounds of the present invention was evaluated by means of a passive cutaneous anaphylaxis (PCA) in rats.

A passive sensitization was conducted by a subcutaneous administration of a solution of anti-DNP-Asc (2,4-dinitrophenyl ascaris) diluted with a physiological saline solution to four places of the back of a group of six male rats of Wister strain (six weeks age) whose backs were shaved. One hour after the oral administration of the test compound, a mixture of same amounts of DNP-Asc solution (5 mg/ml) and 2% Evans blue solution was intravenously administered to induce a PCA reaction. After 30 minutes, the rats were killed by decapitation and draining out the blood, the parts having blue spots were cut out and the amount of the leaked dye was measured. Thus, the skin was dissolved by 2N aqueous solution of potassium hydroxide, centrifuged after adding 2N aqueous solution of phosphoric acid and acetone and the amount of the dye was measured from the absorbance at 620 nm of the resulting supernatant liquid whereby the inhibiting rate against the dye leakage was determined.

As a result, a significant inhibitory action against the dye leakage was observed in a group where 20 mg/kg of the compounds of the present invention were orally administered as compared with the control.

(3) Inhibitory Action Against the Bronchocontracting Reaction Induced by LTD₄.

The inhibitory action of the compounds of the present invention against the bronchocontracting reaction induced by LTD₄ was measured according to a modified Konzett and Rossler's method using Hartley male guinea pigs [cf. Japan. J. Pharmacol., vol.30, 537(1980)].

As a result, an inhibitory action which was as strong as that after 1 hour from the administration was observed in the case of the compounds of the present invention represented by the general formula (8) even after 5 hours from the administration to the bronchocontracting reaction in guinea pigs induced by LTD₄. On the contrary, in the case of the

known compounds having no substituent at the 7-position of the present invention compound, the inhibitory action against the bronchial contraction was hardly noted after 5 hours from their administration. It is believed that such an effect of elongating the duration of the action is due to the structural character of the compound of the present invention that they have a substituent at the 7-position of the structure represented by the general formula (8).

5 It is clear from the result of the above-mentioned pharmacological experiments that the pyrido[2,3-d]pyrimidine derivatives of the present invention exhibit an excellent bronchodilating action. It has been known that the pyrido[2,3-d]pyrimidine derivatives which are disclosed in the Japanese Laid-Open Patent Publication Sho-63/45279 exhibit an antiallergic action as mentioned already. However, although such an action is able to prevent the onset of asthma symptoms participated by the chemical mediators such as histamine, it is not capable of dilating the contracted bronchus and
10 of remediying the laboring breath of asthma. Thus, the present invention offers a rapid-acting agent which directly acts on the contracted tracheal smooth muscle to make it relaxed so that the symptoms of laboring breath upon the asthma onset can be relieved and said agent is quite useful as a bronchodilator which can be used as a remedy not only for allergic asthma but also for various bronchial asthma such as endogenous asthma, exogenous asthma and dust asthma.

15 The pyrido[2,3-d]pyrimidine derivatives represented by the general formulae (1) to (8) are novel substances and they exhibit both excellent bronchodilating and antiallergic actions and are quite useful as the agents for various allergic diseases such as allergic rhinitis, allegic conjunctivitis, urticaris, allegic skin diseases, etc. as well as for bronchial asthma. In addition, the compounds represented by the general formula (8) have a characteristic feature that duration of their action is long and are advantageous as the pharmaceuticals wherein their administering frequency per day or
20 their dose can be reduced.

25 (Examples)

The compound of the present invention can be made into pharmaceutical preparations by a combination with a suitable pharmaceutical carriers or diluents. They can be made into various types of preparations by common methods and are able to be made into solid, semisolid, liquid or aerosol formulations for administrations by oral or parenteral means.

In preparing the preparations, the compound of the present invention may be used in the form of their pharmaceutically acceptable salts, and also can be used either solely or jointly together with other pharmaceutically-active components.

30 In the case of the preparations for oral administration, the compound of the present invention as it is or together with commonly-used excipients such as a suitable additive (e.g. lactose, mannitol, corn starch, potato starch, etc.) is mixed with binders such as crystalline cellulose, cellulose derivatives, gum arabicum, corn starch, gelatin, etc., disintegrating agents such as corn starch, potato starch, potassium carboxymethylcellulose, etc., lubricating agents such as talc, magnesium stearate, etc. and others including bulking agents, moisturizing agents, buffers, preservatives, perfumes and the like to give tablets, diluted powders, granules or capsules.

35 In the case of injections, it is possible to prepare the solutions or the suspensions in an aqueous and nonaqueous solvents such as distilled water for injection, physiological saline solution, Ringer's solution, plant oil, synthetic fatty acid glycerides, higher fatty acid esters, propylene glycol, etc.

40 It is also possible, depending upon the state of the patient and the type of the disease, to prepare the pharmaceutical preparations which are other than those which were mentioned already and are suitable for the therapy such as, for example, inhalating agents, aerosol agents, suppositories, ointments, poultices, eye drops, etc.

45 The preferred dose of the compound of the present invention may vary depending upon the object to be administered, form of the preparation, method for the administration, term for the administration, etc. and, in order to achieve a desired effect, 1-1,000 mg per day, preferably 5-500 mg per day may be usually given to common adults by oral route at one time or by a divided manner for several times a day.

In the case of a parenteral administration such as by injection, it is preferred that, due to the influence of the absorption, etc., a level of from 1/3 to 1/10 of the above-given dose by oral route is administered.

EP 0 696 590 A1

As hereunder, some examples of the pharmaceutical formulations containing the compound of the present invention as an effective component are given though the present invention is not limited thereto.

Table 2

5 (Formulation Example 1; Tablet)	
Components	Amount per Tablet
Compound of this Invention	20 mg
Lactose	130 mg
Crystalline cellulose	40 mg
Magnesium stearate	10 mg
Total	200 mg

Table 3

20 (Formulation Example 2; Injection)	
Components	Amount per Ampoule
Compound of the Invention	5 mg
Sodium chloride	q.s.
Distilled water for injection	q.s.
Total	1 ml


Table 4

35 (Formulation Example 3: Agent for inhalation)	
Components	Amount per Inhalation
Compound of the Invention	1 g
Lactose	5 g
Total	6 g

Claims


45 1. The use of a pyrido [2,3-d] pyrimidine derivative represented by the general formula (A) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for dilating a contracted bronchus or for treating laboured

breathing due to asthma:




15 wherein R¹ and R² are the same or different and each of them is hydrogen, alkyl or benzyl; R³ is hydrogen, hydroxyl, dialkylaminomethyleneamino or -NH-X; X is hydrogen, alkyl, alkenyl, hydroxyl, amino, hydroxyalkyl, benzyl or acyl; R⁴ is hydrogen, alkyl, halogen, nitro, amino, hydroxy, cyano, carboxyl, alkoxy carbonyl, alkoxysulfonyl, aminosulfonyl, dialylaminosulfonyl or sulfo; and R⁵ is hydrogen, alkyl or amino.

20 2. A compound represented by the general formula (1) or a pharmaceutically acceptable salt thereof:




35 wherein Ra¹ and Rb¹ are the same or different and each of them is alkyl; Rc¹ is amino or alkylamino; and Re¹ is alkyl.

35 3. A compound represented by the general formula (2) or a pharmaceutically acceptable salt thereof:




50 wherein Ra² and Rb² are the same or different and each of them is alkyl; and Rd² is alkoxy carbonyl.

4. A compound represented by the general formula (3) or a pharmaceutically acceptable salt thereof:




15 wherein Rc^3 is amino, alkylamino or benzylamino.

15 5. A compound represented by the general formula (4) or a pharmaceutically acceptable salt thereof:



30 wherein one of Ra^4 and Rb^4 is hydrogen whilst the other is alkyl; and Rc^4 is amino or alkylamino.

6. A compound represented by the general formula (5) or a pharmaceutically acceptable salt thereof:




45 wherein Ra^5 and Rb^5 are different and each of them is alkyl; and Rc^5 is amino or alkylamino.

50


55

7. A compound represented by the general formula (6) or a pharmaceutically acceptable salt thereof:




15 wherein Ra⁶ is hydrogen or alkyl; and Rc⁶ is amino, alkylamino or benzylamino.

8. A compound represented by the general formula (7) or a pharmaceutically acceptable salt thereof:




30 wherein Ra⁷ and Rb⁷ are the same or different and each of them is alkyl; and Rc⁷ is acylamino, alkylamino, benzylamino or dialkylaminomethyleneamino.

35 9. A compound represented by the general formula (8) or a pharmaceutically acceptable salt thereof:



50 wherein Ra⁸ and Rb⁸ are the same or different and each of them is alkyl; Xc is hydrogen, alkyl or acyl; and Yd is alkyl, halogen, nitro, amino, hydroxyl, benzyloxy, cyano, carboxyl, alkoxy carbonyl, alkoxy sulfonyl, aminosulfonyl, dialkylaminosulfonyl or sulfo.

10. A bronchodilator containing a pyrido [2,3-d] pyrimidine derivative represented by the general formula (A) or a pharmaceutically acceptable salt thereof as an effective component:



wherein R¹ and R² are the same or different and each of them is hydrogen, alkyl or benzyl; R³ is hydrogen, hydroxyl, dialkylaminomethyleneamino or -NH-X; X is hydrogen, alkyl, alkenyl, hydroxyl, amino, hydroxalkyl, benzyl or acyl; R⁴ is hydrogen, alkyl, halogen, nitro, amino, hydroxy, cyano, carboxyl, alkoxy carbonyl, alkoxy sulfonyl, aminosulfonyl, dialylaminosulfonyl or sulfo; and R⁵ is hydrogen, alkyl or amino.

20

25

30

35

40

45

50

55



EUROPEAN SEARCH REPORT

Application Number
EP 95 10 9391

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claims	
X	CHEM. HETEROCYCL. COMPOUNDS , vol. 19, no. 6, 1983 pages 674-677, CHERDANTSEVA N.M. ET AL. 'Synthesis of pyrido[2,3-d]pyrimidines on the basis of 5-formyl-6-aminouracils' * pages 674 and 676; compound Vf * & KHIM. GETEROSIKL. SOEDIN., vol. 19, no. 6, 1983 pages 834-837, ---	3	C07D471/04 A61K31/505 //(C07D471/04, 239:00,221:00)
X	MONATSHEFTE FUR CHEMIE (CHEMICAL MONTHLY), vol. 117, 1986 pages 879-882, RODGERS G.R. & NEISH W.J.P. 'Linear expanded xanthines' * page 881; compound 10 *	3	
X	EP-A-0 243 311 (NIPPON ZOKI PHARMACEUTICAL CO. LTD.) 28 October 1987 * page 20 - page 23; claims 1,4,7,9-11,15,18-20 * * compound 6 *	1,6,8,10	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
X	* compounds 7, 8, 10, 19; 7th, 8th and 9th compound on page 4 *	6	
D	& JP-A-63 045 279 (NIPPON ZOKI PHARM.) 26 February 1988 ---	8	
X	WO-A-92 08719 (BASF AKTIENGESELLSCHAFT) 29 May 1992 * claim 1, formula Ib * * page 62; example 5.011 * * claim 1, formula Ia * * page 60; example 3.007 *	3,5,6,9	
X	---	3	
X	---	5,6,9	
	---	-/-	
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
MUNICH		20 October 1995	Hartrampf, G
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : see-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, not published on, or after the filing date D : document cited in the application L : document cited for other reasons R : member of the same patent family, corresponding document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 9391

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	<p>CHEM. HETEROCYCL. COMPOUNDS , vol. 29, no. 3, 1993 pages 335-338, BUROVA O.A. ET AL. 'Pyrido[2,3-d]pyrimidines. 7. Reactions of 1,3-dimethyl-5,7-dichloro-6-nitropyrido[2, 3-d]pyrimidine-2,4-dione with amines. Synthesis of derivatives of triazolo(4',5':4,5)pyrido[2,3-d]pyrimidine ' * page 337; compound VIIa * & KHIM. GETEROSIKL. SOEDIN., no. 3, 1993 pages 398-401, ---</p>	9	
X	DIE PHARMAZIE, vol. 48, no. 7, July 1993 pages 509-513, HEBER D. ET AL. 'Synthesis and positive inotropic activity of several 5-aminopyrido[2,3-d]pyrimidines' * compounds 17a, 17b and 17c *	8,9	
X	* compounds 6a, 6b and 6c; compound 10; compound 11; compounds 12a, 12b and 12c *	8	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
X	* compound 19 *	9	
A	---	3	
		-/-	
<p>The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
MUNICH	20 October 1995	Hartrampf, G	
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 9391

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DIE PHARMAZIE, vol. 48, no. 7, July 1993 pages 537-541, HEBER D. ET AL. 'Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-2,4-dione in cardiac muscle from guinea-pig and man' * compound 11 *	8,9	
X	* compounds 3, 4 and 13 *	8	
X	* compound 14; compound 12 *	9	
A	-----	3-5	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
<p>The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
MUNICH	20 October 1995	Hartrampf, G	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			